MX9704910A - Formula de liberacion controlada (albuterol). - Google Patents

Formula de liberacion controlada (albuterol).

Info

Publication number
MX9704910A
MX9704910A MX9704910A MX9704910A MX9704910A MX 9704910 A MX9704910 A MX 9704910A MX 9704910 A MX9704910 A MX 9704910A MX 9704910 A MX9704910 A MX 9704910A MX 9704910 A MX9704910 A MX 9704910A
Authority
MX
Mexico
Prior art keywords
albuterol
controlled release
release formulation
sustained release
pharmaceutical formulation
Prior art date
Application number
MX9704910A
Other languages
English (en)
Inventor
Anand R Baichwal
Troy W Mccall
Original Assignee
Mendell Co Inc Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24207743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9704910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward
Publication of MX9704910A publication Critical patent/MX9704910A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels

Abstract

Se proporciona una formula farmacéutica de liberacion sostenida y métodos para producirla y utilizarla. La formula farmacéutica de liberacion sostenida incluye un excipiente de liberacion sostenida que incluye a su vez un agente gelificante, un diluyente farmacéuticamente inerte, un material hidrofobico opcional y/o revestimiento hidrofobico, y un medicamento para administracion oral sostenida.
MX9704910A 1995-11-03 1997-06-27 Formula de liberacion controlada (albuterol). MX9704910A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/553,008 US5662933A (en) 1993-09-09 1995-11-03 Controlled release formulation (albuterol)

Publications (1)

Publication Number Publication Date
MX9704910A true MX9704910A (es) 1998-06-30

Family

ID=24207743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704910A MX9704910A (es) 1995-11-03 1997-06-27 Formula de liberacion controlada (albuterol).

Country Status (12)

Country Link
US (2) US5662933A (es)
EP (2) EP2286796A3 (es)
JP (1) JP3250737B2 (es)
KR (2) KR100264024B1 (es)
AT (1) ATE507820T1 (es)
AU (1) AU7725396A (es)
CA (1) CA2208230C (es)
DE (1) DE69638364D1 (es)
DK (1) DK0804166T3 (es)
ES (1) ES2366278T3 (es)
MX (1) MX9704910A (es)
WO (1) WO1997016172A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
EP0869772B1 (en) * 1995-12-27 2001-10-04 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6929936B1 (en) * 1997-07-18 2005-08-16 Danisco A/S Composition comprising an enzyme having galactose oxidase activity and use thereof
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
AU731693B2 (en) * 1997-09-25 2001-04-05 Bayer Intellectual Property Gmbh Drug formulation having controlled release of active compound
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EP1056740A1 (en) * 1998-02-20 2000-12-06 Fine Chemicals Corporation (Proprietary) Limited Process for the production of optically enriched (r)- or (s)-albuterol
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US6416786B1 (en) 1998-12-11 2002-07-09 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
KR100844295B1 (ko) * 1999-06-04 2008-07-07 알자 코포레이션 이식성 겔 조성물 및 이의 제조방법
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ATE391495T1 (de) * 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7056531B1 (en) 2000-05-04 2006-06-06 Nature's Way Products, Inc. Sustained release compositions for orally administered substances and methods
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
ES2436523T3 (es) * 2001-03-13 2014-01-02 Endo Pharmaceuticals Inc. Formas de dosificación terapéutica
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
PL208484B1 (pl) * 2001-07-06 2011-05-31 Penwest Pharmaceuticals Company Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu
WO2003004031A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
CA2494281A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US20060177497A1 (en) * 2003-07-21 2006-08-10 Bio Dar Ltd. Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention
EP1670442A4 (en) * 2003-09-19 2011-09-14 Penwest Pharmaceuticals Co DOSAGE FORMS WITH DELAYED RELEASE
JP2007519608A (ja) * 2003-09-19 2007-07-19 ペンウェスト ファーマシューティカルズ カンパニー 時間治療用剤形
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
WO2006070930A1 (en) 2004-12-27 2006-07-06 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
CN101351196B (zh) * 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
AU2011224350B2 (en) * 2010-03-09 2015-07-02 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
NZ603170A (en) 2010-05-10 2015-04-24 Euro Celtique Sa Combination of active loaded granules with additional actives
ES2408343B2 (es) 2010-05-10 2014-07-17 Euro-Celtique, Sa Composiciones farmacéuticas que comprenden hidromorfona y naloxona
JP5838199B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を含まない顆粒およびその顆粒を含む錠剤の製造
EP2744496A4 (en) * 2011-08-16 2015-04-08 Baker Idi Heart And Diabetes Inst Holdings Ltd FORMULATIONS WITH TAXED RELEASE
DE102012014848A1 (de) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Heilerde-Zubereitung
MX2016006279A (es) 2013-11-13 2016-09-07 Euro Celtique Sa Hidromorfona y naloxona para el tratamiento del dolor y el sindrome de disfuncion intestinal opiacea.
BR112017013015A2 (pt) 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
WO2018143423A1 (ja) * 2017-02-03 2018-08-09 株式会社東洋新薬 固形製剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
EP0272336B1 (de) * 1986-12-18 1991-10-23 Kurt H. Prof. Dr. Bauer Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
DE68915494T2 (de) * 1988-03-09 1995-01-05 Snow Brand Milk Products Co Ltd Zubereitung mit verzögerter freigabe durch verwendung von alginaten.
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs

Also Published As

Publication number Publication date
EP0804166B1 (en) 2011-05-04
DK0804166T3 (da) 2011-08-15
JPH10507210A (ja) 1998-07-14
ATE507820T1 (de) 2011-05-15
US5662933A (en) 1997-09-02
ES2366278T3 (es) 2011-10-18
AU7725396A (en) 1997-05-22
KR20000018064A (ko) 2000-04-06
DE69638364D1 (de) 2011-06-16
CA2208230A1 (en) 1997-05-09
KR100264024B1 (ko) 2000-09-01
CA2208230C (en) 2001-12-25
EP2286796A3 (en) 2012-02-22
WO1997016172A1 (en) 1997-05-09
JP3250737B2 (ja) 2002-01-28
EP2286796A2 (en) 2011-02-23
US5958456A (en) 1999-09-28
EP0804166A4 (en) 2004-12-29
EP0804166A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
MX9704910A (es) Formula de liberacion controlada (albuterol).
CA2171844A1 (en) Sustained release formulations for 24 hour release of metoprolol
CA2164619A1 (en) Once-a-day metoprolol oral dosage form
HU9503054D0 (en) Controlled release oxybutynin formulations
CA2216828A1 (en) Controlled release insufflation carrier for medicaments
AU671384B2 (en) Sustained release drug formulation containing a tramadol salt
GEP20053420B (en) Sustained Release Ranolanolazine Formulation
CA2111002A1 (en) Non-Chlorofluorocarbon Aerosol Formulations
AU1534699A (en) Osmotic dosage form comprising first and second coats
EP1468679A3 (en) Controlled release formulation containing tramadol
AU651894B2 (en) Matrix tablet permitting the sustained release of indapamide after oral administration
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
NZ264487A (en) Tetracycline based prodrug conjugate, pharmaceutical compositions thereof
JO2082B1 (en) The formed granules of clavulinite and excipients
WO1997037640A3 (en) Uniform drug delivery therapy
AU5805096A (en) Transdermal therapeutic system (TTS) for the administration of testosterone
CA2249637A1 (en) Uniform drug delivery therapy

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: KONINKLIJKE DOUWE EGBERTS B.V.